An early stage trial of an investigational therapy for amyotrophic lateral sclerosis (ALS) suggests that people could tolerate the experimental drug and, in exploratory results, the experimental drug was linked to possible slower progression in people with a genetic form of the disease caused by mutations in a gene called superoxide dismutase 1 (SOD1).
from Latest Science News -- ScienceDaily http://bit.ly/2V6tu4A
via IFTTT
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment